Subscribe

Neil Canavan

Authored Articles

14 New Genetic Markers Predict Risk for Prostate Cancer
Neil Canavan
Personalized Medicine, Prostate Cancer, Solid Tumors
April 2014, Vol 5, No 3
Read Article
Task Force Recommends Annual Screening for Lung Cancer in High-Risk Populations
Neil Canavan
Lung Cancer
February 2014, Vol 5, No 1
Read Article
Higher Copays for Imatinib Lead to Medication Nonadherence in Patients with CML
Neil Canavan
Economics & Value, Economics of Cancer Care
February 2014, Vol 5, No 1
Read Article
ASCO Proposes New Reimbursement Model by Medicare for Cancer Care
Neil Canavan
Economics & Value, Economics of Cancer Care
February 2014, Vol 5, No 1
Read Article
Rising Costs of Cancer Survivorship a Growing Concern
Neil Canavan
Economics & Value, Economics of Cancer Care, Survivorship
November 2013, Vol 4, No 9
Read Article
Costs to Medicare Nearly Twice as High for Hospital Outpatient versus Community-Based Oncology Services
Neil Canavan
Economics & Value, Economics of Cancer Care
October 2013, Vol 4, No 8
Read Article
Patient-Reported Outcomes More Common in EU Labeling than FDA Labeling of Drug Approved for Lung Cancer
Neil Canavan
Economics & Value, Economics of Cancer Care
June 2013, Vol 4, No 5
Read Article
Radiation Breakdown: All That Glitters Is Not Gold
Neil Canavan
ACCC Annual Meeting
June 2012, Vol 3, No 4
Read Article
More Revenue, Less Waste: Tips for Optimizing Financial Performance
Neil Canavan
ACCC Annual Meeting
June 2012, Vol 3, No 4
Read Article
Can Pathways Improve Quality of Care While Reducing Cost?
Neil Canavan
ACCC Annual Meeting
June 2012, Vol 3, No 4
Read Article
Coping with Cancer Drug Shortages: Practical Tips
Neil Canavan
ACCC Annual Meeting
May 2012, Vol 3, No 3
Read Article
Cost-Containment Efforts Top Trend in Community Cancer Centers
Neil Canavan
ACCC Annual Meeting
May 2012, Vol 3, No 3
Read Article
Ready or Not, Value-Based Purchasing Is Coming Near You
Neil Canavan
ACCC Annual Meeting
May 2012, Vol 3, No 3
Read Article
First Randomized Comparison of Catheter-Directed Thrombolysis versus Standard Care for DVT Prophylaxis
Neil Canavan
ASH Highlights, ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
Read Article
Ponatinib Overcomes Hard-to-Treat T315I Mutation in Patients with CML/ALL
Neil Canavan
ASH Highlights, ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
Read Article
Significant Cost of Treating Myeloproliferative Neoplasms
Neil Canavan
ASH Highlights, ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
Read Article
The Oncology Drug Pipeline Is Promising
Neil Canavan
ASCO Annual Meeting
August 2011, Vol 2, No 5
Read Article
Off-Label Drug Use, Advanced Technologies Driving Up Medicare Cost of Cancer Care
Neil Canavan
ASCO Annual Meeting
August 2011, Vol 2, No 5
Read Article
Impressive Results with New Drugs for Advanced Prostate Cancer
Neil Canavan
ASCO Annual Meeting
August 2011, Vol 2, No 5
Read Article
Emerging Regimen for Metastatic Pancreatic Cancer Has Survival Benefit, but Is It Cost-Effective?
Neil Canavan
ASCO Annual Meeting
August 2011, Vol 2, No 5
Read Article

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.